07Nov 2021
Nemolizumab plus topical agents in patients with atopic dermatitis and moderate‐to‐severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long‐term studies

Nemolizumab plus topical agents in patients with atopic dermatitis and moderate‐to‐severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long‐term studies

Interleukin (IL)‐31 affects the inflammatory response, is involved in epidermal barrier disruption in atopic dermatitis (AD), and plays a key role in pruritus. Nemolizumab, a humanized monoclonal antibody against IL‐31 receptor A, reduced pruritus in patients with AD after a 16‐week administration period. To examine the long‐term effectiveness and safety of nemolizumab in patients aged ≥13 years with AD and inadequately controlled moderate‐to‐severe pruritus. In two long‐term phase III studies, nemolizumab 60 mg every 4 weeks (Q4W) was administered subcutaneously, concomitantly with topical treatments. Study‐JP01 patients received double‐blind nemolizumab or placebo for 16 weeks, and then entered a 52‐week extension period in which all patients received nemolizumab (nemolizumab/nemolizumab and placebo/nemolizumab groups). Study‐JP02 patients received nemolizumab for 52 weeks...

  • #dermatology

Like

Save

Share